Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. ...
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT03361306
- Locations
- ๐บ๐ธ
Levine Cancer Institute, Charlotte, North Carolina, United States
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT03227432
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03168100
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Combination Study for High Risk Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT03104270
- Locations
- ๐บ๐ธ
Robert A. Moss, MD, FACP, Inc, Fountain Valley, California, United States
๐บ๐ธPacific Cancer Care, Monterey, California, United States
๐บ๐ธCalifornia Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT03030261
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธColorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
๐จ๐ฆUniversity Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT03023527
- Locations
- ๐ช๐ธ
Hospital Clinic, Barcelona, Spain
๐ช๐ธICO Badalona, Badalona, Spain
๐ช๐ธHospital Ramรณn y Cajal, Madrid, Spain
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03003728
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03000634
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 47
- Registration Number
- NCT02969837
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธNorthShore University Health System, Evanston, Illinois, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Early Patient Access Treatment Use Protocol CA204-220
- Conditions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02856438
- Locations
- ๐ฏ๐ต
Local Institution, Osaka-shi, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.